Motor evaluation of Parkinson’s disease patients through video consultations in the Brazilian public health system – a real life feasibility study
Objective: To assess the feasibility and quality of evaluating motor symptoms through video consultations for Parkinson disease’s (PD) patients in the Brazilian public health system.…WATCH-PD: Wearable Assessments in the Clinic and Home in Parkinson’s Disease: Baseline Analyses
Objective: To provide a profile of early Parkinson’s disease (PD) using clinical and digital measures and determine whether digital measures can differentiate PD and controls…Efficacy of opicapone according to different levodopa daily intakes in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuation according to different levodopa daily intakes. Background: OPC proved…Effects of Opicapone on Sleep in Patients with Parkinson’s Disease and Motor Fluctuations
Objective: To assess the effects of opicapone (OPC: 50 mg, once-daily) on sleep in patients with Parkinson’s disease (PD) and motor fluctuations. Background: OPC is…PARK-BAND training program for Parkinson’s disease in clinical settings: A feasibility study.
Objective: To describe indicators of feasibility, including acceptability and safety, of Power training (PT) in Parkinson’s Disease (PD). Background: PT is a specific method of…Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Europe vs North America
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD)…The effect of Nordic Walking on respiratory function, pain and gait in Parkinson’s disease
Objective: To assess the effect of rehabilitation program based on exercises and Nordic Walking (NW) on respiratory function, range of chest mobility, pain and gait…The mitochondrial targeted drug SBT-272 attenuates dopaminergic neuron loss, alpha-synuclein burden and neuroinflammation in a mouse model of Parkinson’s Disease
Objective: To assess the preclinical efficacy of the investigational drug SBT-272 in a mouse model of Parkinson’s Disease (PD). Background: SBT-272 is a peptidomimetic drug…ABBV-0805, a novel α-synuclein oligomer selective antibody, prolonged lifespan and prevented accumulation of α-synuclein pathology in mouse models of Parkinson’s disease
Objective: We report on the pharmacological characteristics of ABBV-0805 (BAN0805), a monoclonal antibody that exhibits a high selectivity for human α-synuclein oligomers and very low…Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the influence of onset of motor fluctuation (OMF) on the response to opicapone (OPC) treatment in patients with Parkinson’s disease…
- « Previous Page
- 1
- …
- 59
- 60
- 61
- 62
- 63
- …
- 132
- Next Page »